title: FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
authors: Department of Gastroenterology, Avicenne Hospital, Bobigny, France. Electronic address: thomas.aparicio@avc.aphp.fr.
authors: Thomas
authors: T
authors: Aparicio
authors: Department of Oncology, Institut de Cancérologie de l'Ouest Nantes-Angers, France.
authors: Benjamin
authors: B
authors: Linot
authors: INSERM, Dijon, France.
authors: Karine
authors: K
authors: Le Malicot
authors: Department of Gastroenterology, CHU Reims, France.
authors: Olivier
authors: O
authors: Bouché
authors: Department of Gastrointestinal Oncology, Gustave Roussy, Villejuif, France.
authors: Valérie
authors: V
authors: Boige
authors: Department of Gastroenterology, Centre Antoine Lacassagne, Nice, France.
authors: Eric
authors: E
authors: François
authors: Department of Oncology, Centre George Francois Leclerc, Dijon, France.
authors: Francois
authors: F
authors: Ghiringhelli
authors: Department of Gastroenterology, CH Orléans, France.
authors: Jean-Louis
authors: JL
authors: Legoux
authors: Department of Oncology, Centre Paul Strauss, Strasbourg, France.
authors: Meher
authors: M
authors: Ben Abdelghani
authors: Department of Gastroenterology, CHU Bellevue Nord, Saint Etienne, France.
authors: Jean-Marc
authors: JM
authors: Phelip
authors: Department of Gastroenterology, CH Les Oudaries, La Roche sur Yon, France.
authors: Roger
authors: R
authors: Faroux
authors: Department of Gastroenterology, CHU La Timone, Aix-Marseille University, Marseille, France.
authors: Laetitia
authors: L
authors: Dahan
authors: Department of Gastroenterology, Georges Pompidou Hospital, Paris, France.
authors: Julien
authors: J
authors: Taieb
authors: Department of Gastroenterology, CHU Le Bocage, Dijon, France.
authors: Laurent
authors: L
authors: Bedenne
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D002955:Leucovorin / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin